×
About 866 results

ALLMedicine™ Oncology Treatment Center

Research & Reviews  359 results

Gynecologic oncology treatment modifications or delays in response to the COVID-19 pand...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8080163
Gynecologic Oncology; Piedimonte S, Li S et. al.

May 4th, 2021 - To compare gynecologic oncology surgical treatment modifications and delays during the first wave of the COVID-19 pandemic between a publicly funded Canadian versus a privately funded American cancer center. This is a retrospective cohort study of...

Probiotic Supplements on Oncology Patients' Treatment-Related Side Effects: A Systemati...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8074215
International Journal of Environmental Research and Publi... Rodriguez-Arrastia M, Martinez-Ortigosa A et. al.

Apr 30th, 2021 - Cancer affects more than 19.3 million people and has become the second leading cause of death worldwide. Chemo- and radiotherapy, the most common procedures in these patients, often produce unpleasant treatment-related side effects that have a dir...

Enhanced recovery after surgery protocols improve time to return to intended oncology t...
https://doi.org/10.1136/ijgc-2021-002495
International Journal of Gynecological Cancer : Official ... Tankou JI, Foley O et. al.

Apr 16th, 2021 - The objective of this study was to determine whether the implementation of an enhanced recovery after surgery (ERAS) protocol is associated with earlier return to intended oncology treatment following interval cytoreductive surgery for advanced gy...

Rhabdomyosarcoma.
https://doi.org/10.1002/pbc.28254
Pediatric Blood & Cancer; Yechieli RL, Mandeville HC et. al.

Apr 5th, 2021 - Rhabdomyosarcoma is a heterogeneous disease both in presentation and histology. Improvements in a multimodality therapy resulted in the improved overall survival for patients with a low-risk and intermediate-risk disease but not for patients with ...

Reducing distress and depression in cancer patients during survivorship.
https://doi.org/10.1002/pon.5683
Psycho-oncology Molinaro J, Banerjee A et. al.

Apr 2nd, 2021 - Distress and depression are prevalent in cancer patients throughout survivorship and are associated with adverse outcomes. This study examines the association between outpatient psycho-oncology treatment and distress and depression in cancer patie...

see more →

Guidelines  31 results

KDIGO Controversies Conference on onco-nephrology: understanding kidney impairment and ...
https://doi.org/10.1016/j.kint.2020.06.046
Kidney International; Porta C, Bamias A et. al.

Oct 31st, 2020 - The association between kidney disease and cancer is multifaceted and complex. Persons with chronic kidney disease (CKD) have an increased incidence of cancer, and both cancer and cancer treatments can cause impaired kidney function. Renal issues ...

Investigating MET Exon 14 Mutations in Patients With NSCLC
https://www.targetedonc.com/view/investigating-met-exon-14-mutations-in-patients-with-nsclc

May 28th, 2020 - Mark M. Awad, MD, PhD, clinical director of the Thoracic Oncology Treatment Center at Dana-Farber Cancer Institute and assistant professor of Medicine at Harvard Medical School, discusses the characterization of patients with non–small cell lung c...

Standardizing Normal Tissue Contouring for Radiation Therapy Treatment Planning: Executive summary of an ASTRO Consensus Paper
https://www.practicalradonc.org/article/S1879-8500(18)30353-9/abstract
Wright,J.,et al

Jan 20th, 2019 - Standardization improves patient safety, efficiency, and accuracy in radiation oncology treatment. This consensus guidance represents an ASTRO quality initiative to provide recommendations for the standardization of normal tissue contouring perfor...

ASTRO Consensus Statement on Standardizing Normal Tissue Contouring for Radiation Therapy Treatment Planning: Executive Summary
https://www.astro.org/Patient-Care-and-Research/Clinical-Practice-Statements/Contouring-Consensus-Guidance-Document

Jan 20th, 2019 - This document provides tabled recommendations for normal tissues contouring during external beam treatment planning for each anotomical site in all definitive cases and those that should be considered in specific clinical scenarios. Additionally, ...

Morbidity and Mortality Rates Following Cytoreductive Surgery Combined With Hyperthermic Intraperitoneal Chemotherapy Compared With Other High-Risk Surgical Oncology Procedures
https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2720582
Foster,J.

Jan 10th, 2019 - Comparative analysis revealed CRS/HIPEC to be safe, often safer across the spectrum of NSQIP safety metrics when compared with similar-risk oncologic procedures. Patient selection was important in achieving observed outcomes. High complication rat...

see more →

Drugs  2 results see all →

Clinicaltrials.gov  435 results

Gynecologic oncology treatment modifications or delays in response to the COVID-19 pand...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8080163
Gynecologic Oncology; Piedimonte S, Li S et. al.

May 4th, 2021 - To compare gynecologic oncology surgical treatment modifications and delays during the first wave of the COVID-19 pandemic between a publicly funded Canadian versus a privately funded American cancer center. This is a retrospective cohort study of...

Probiotic Supplements on Oncology Patients' Treatment-Related Side Effects: A Systemati...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8074215
International Journal of Environmental Research and Publi... Rodriguez-Arrastia M, Martinez-Ortigosa A et. al.

Apr 30th, 2021 - Cancer affects more than 19.3 million people and has become the second leading cause of death worldwide. Chemo- and radiotherapy, the most common procedures in these patients, often produce unpleasant treatment-related side effects that have a dir...

Enhanced recovery after surgery protocols improve time to return to intended oncology t...
https://doi.org/10.1136/ijgc-2021-002495
International Journal of Gynecological Cancer : Official ... Tankou JI, Foley O et. al.

Apr 16th, 2021 - The objective of this study was to determine whether the implementation of an enhanced recovery after surgery (ERAS) protocol is associated with earlier return to intended oncology treatment following interval cytoreductive surgery for advanced gy...

Rhabdomyosarcoma.
https://doi.org/10.1002/pbc.28254
Pediatric Blood & Cancer; Yechieli RL, Mandeville HC et. al.

Apr 5th, 2021 - Rhabdomyosarcoma is a heterogeneous disease both in presentation and histology. Improvements in a multimodality therapy resulted in the improved overall survival for patients with a low-risk and intermediate-risk disease but not for patients with ...

Reducing distress and depression in cancer patients during survivorship.
https://doi.org/10.1002/pon.5683
Psycho-oncology Molinaro J, Banerjee A et. al.

Apr 2nd, 2021 - Distress and depression are prevalent in cancer patients throughout survivorship and are associated with adverse outcomes. This study examines the association between outpatient psycho-oncology treatment and distress and depression in cancer patie...

see more →

News  39 results

Florida Cancer Center Founder Faces Criminal Trial for Conspiracy
https://www.medscape.com/viewarticle/945273

Feb 3rd, 2021 - The criminal trial of William Harwin, MD, founder and former president of Florida Cancer Specialists, a multisite practice headquartered in Fort Myers, is set for June, according to federal documents reviewed by Medscape Medical News. Harwin is ch...

'Long-Running' Conspiracy: Cancer Center's Ex-Top Doc Indicted
https://www.staging.medscape.com/viewarticle/938197

Sep 27th, 2020 - William Harwin, MD, founder and former president of Florida Cancer Specialists, a large multisite practice, has been indicted by a federal grand jury for conspiring to restrict patient choice and allocate medical and radiation oncology treatment i...

'Long-Running' Conspiracy: Cancer Center's Ex-Top Doc Indicted
https://www.medscape.com/viewarticle/938197

Sep 27th, 2020 - William Harwin, MD, founder and former president of Florida Cancer Specialists, a large multisite practice, has been indicted by a federal grand jury for conspiring to restrict patient choice and allocate medical and radiation oncology treatment i...

Investigating MET Exon 14 Mutations in Patients With NSCLC
https://www.targetedonc.com/view/investigating-met-exon-14-mutations-in-patients-with-nsclc

May 28th, 2020 - Mark M. Awad, MD, PhD, clinical director of the Thoracic Oncology Treatment Center at Dana-Farber Cancer Institute and assistant professor of Medicine at Harvard Medical School, discusses the characterization of patients with non–small cell lung c...

Oncologists agree with AI treatment decisions about half the time
https://www.mdedge.com/fedprac/avaho/article/206866/breast-cancer/oncologists-agree-ai-treatment-decisions-about-half-time?channel=263
Will Pass

Aug 22nd, 2019 - When it comes to treatment recommendations for high-risk breast cancer, oncologists agree with a leading artificial intelligence platform about half the time, according to investigators. In the first study of its kind, involving 10 Chinese oncolog.

see more →